Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma

M. Spisarová, B. Melichar, D. Vitásková, H. Študentová

. 2021 ; 17 (3) : 241-254. [pub] 20201005

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026246

Grantová podpora
17-16614S, 18-12204S Grantová Agentura České Republiky

Sequential administration of single targeted agents has been challenged as the dominant treatment paradigm in patients with metastatic renal cell carcinoma by improved outcomes obtained with combination regimens based on immune checkpoint inhibitors. Most patients treated with sequential monotherapy eventually develop drug resistance and succumb to progressive disease, leading to the search for therapies that would overcome drug resistance and result in a more durable treatment response. Improved outcomes have been demonstrated in Phase III trials in comparison with sunitinib for the combinations of axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab and ipilimumab plus nivolumab. A statistically significant improvement of both progression-free and overall survival has been demonstrated for the axitinib plus pembrolizumab combination.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026246
003      
CZ-PrNML
005      
20211026133058.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2020-0079 $2 doi
035    __
$a (PubMed)33016119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Spisarová, Martina $u Department of Oncology, Palacký University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
245    10
$a Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma / $c M. Spisarová, B. Melichar, D. Vitásková, H. Študentová
520    9_
$a Sequential administration of single targeted agents has been challenged as the dominant treatment paradigm in patients with metastatic renal cell carcinoma by improved outcomes obtained with combination regimens based on immune checkpoint inhibitors. Most patients treated with sequential monotherapy eventually develop drug resistance and succumb to progressive disease, leading to the search for therapies that would overcome drug resistance and result in a more durable treatment response. Improved outcomes have been demonstrated in Phase III trials in comparison with sunitinib for the combinations of axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab and ipilimumab plus nivolumab. A statistically significant improvement of both progression-free and overall survival has been demonstrated for the axitinib plus pembrolizumab combination.
650    _2
$a humanizované monoklonální protilátky $x farmakologie $x terapeutické užití $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a axitinib $x farmakologie $x terapeutické užití $7 D000077784
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x patologie $7 D002292
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory kontrolních bodů $x farmakologie $x terapeutické užití $7 D000082082
650    _2
$a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a bezpečnost $7 D012449
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacký University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic $u Institute of Molecular & Translational Medicine, Palacký University Medical School Teaching Hospital, 77900 Olomouc, Czech Republic
700    1_
$a Vitásková, Denisa $u Department of Oncology, Palacký University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
700    1_
$a Študentová, Hana $u Department of Oncology, Palacký University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 17, č. 3 (2021), s. 241-254
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33016119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133105 $b ABA008
999    __
$a ok $b bmc $g 1715073 $s 1146753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 17 $c 3 $d 241-254 $e 20201005 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
GRA    __
$a 17-16614S, 18-12204S $p Grantová Agentura České Republiky
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace